IM-1617

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameIM-1617
Drug Alias NameIM-1617
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsLarge intestine neoplasmCarcinoma, Non-Small-Cell LungStomach Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunome Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunome Inc
Inactive CompaniesN/A
Active IndicationsLarge intestine neoplasmCarcinoma, Non-Small-Cell LungStomach Neoplasms +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A